Primary Hyperoxaluria Pipeline Shows Promise with 6+ Therapies in Development as Gene Editing Advances
核心洞察
Primary hyperoxaluria (搜索) pipeline features over 6 companies developing more than 6 therapeutic candidates, with notable advances in gene editing and RNA interference therapies.
Arbor Biotechnologies (搜索) achieved a significant milestone in July 2025 with the first patient treated in their Phase 1/2 redePHine trial for ABO-101, a gene-editing therapy for PH1 (搜索).
The FDA has approved two breakthrough therapies: nedosiran (Rivfloza) in September 2023 for PH1 (搜索) patients with preserved kidney function, and lumasiran in November 2020 for both adults and children.
The primary hyperoxaluria (搜索) therapeutic landscape is experiencing significant momentum, with over 6 companies actively developing more than 6 treatment candidates for this rare genetic disorder that affects oxalate metabolism and can lead to severe kidney complications.
Gene Editing Breakthrough Marks New Treatment Frontier
Arbor Biotechnologies (搜索) achieved a major milestone in July 2025 when the first patient was treated in the Phase 1/2 redePHine trial (NCT06839235), evaluating ABO-101, an investigational gene-editing therapy for primary hyperoxaluria type 1 (搜索) (PH1 (搜索)). The initial dosing took place at the Mayo Clinic, and within the 28-day dose-limiting toxicity observation period, no serious adverse events were reported. The study's safety board has recommended moving forward with additional dosing in the trial.
The FDA has recognized the potential of ABO-101 by awarding both Orphan Drug Designation and Rare Pediatric Disease Designation in February 2025. These designations provide Arbor with various incentives, including tax credits, waivers of certain regulatory fees, potential market exclusivity, and eligibility for a pediatric priority review voucher if the therapy gains FDA approval.
Recent FDA Approvals Transform Treatment Options
The regulatory landscape for primary hyperoxaluria (搜索) has been transformed by two significant approvals. In September 2023, the FDA approved nedosiran (Rivfloza) for patients aged nine and older with PH1 (搜索) who have relatively preserved kidney function. This LDHA (搜索)-targeted small interfering RNA therapy effectively reduces urinary oxalate levels.
Additionally, lumasiran, an RNA interference therapy, received approval in November 2020 by both the FDA and the European Union for the treatment of PH1 (搜索) in adults and children. Clinical trials demonstrated that lumasiran significantly lowered urinary oxalate levels in treated patients.
Diverse Pipeline Addresses Unmet Medical Need
The current pipeline encompasses a range of therapeutic approaches across different development stages. Key emerging therapies include CHK-336 from Chinook Therapeutics, BBP-711 from Cantero Therapeutics (搜索), BMN 255 from BioMarin Pharmaceutical, Oxabact from OxThera (搜索), and Nedosiran from Dicerna Pharmaceuticals (搜索).
OxThera (搜索) has advanced furthest in the pipeline with a drug candidate that has reached Phase III development, representing the most advanced stage among the emerging therapies. The pipeline spans various molecule types including monoclonal antibodies, small molecules, peptides, and gene therapies, with routes of administration ranging from oral and intravenous to subcutaneous delivery.
Understanding Primary Hyperoxaluria's Clinical Impact
Primary hyperoxaluria type 1 (搜索) is a rare inherited disorder caused by a deficiency of the liver enzyme alanine-glyoxylate aminotransferase (搜索), leading to overproduction of oxalate. This results in excessive oxalate excretion in urine and the buildup of calcium oxalate in organs, particularly the kidneys. PH1 (搜索) is the most common and severe form of primary hyperoxaluria (搜索), with an estimated prevalence of 1-3 cases per million and an incidence of 1 per 120,000 births annually in Europe.
The condition is characterized by the formation of kidney stones, potential kidney damage, and systemic complications if left untreated. Typical symptoms include severe pain in the lower abdomen, groin, or back, discolored urine, painful or frequent urination, and systemic signs such as fever, nausea, and vomiting. Without proper management, PH1 (搜索) can progress to kidney failure.
Market Dynamics and Development Challenges
The rising prevalence of primary hyperoxaluria (搜索) and increasing demand for disease-specific novel treatments are driving market growth. However, the high cost of treatment and diagnosis for hyperoxaluria, along with limited research and development resources, present significant barriers to market expansion.
Companies across the therapeutic landscape include established pharmaceutical leaders such as Alnylam Pharmaceuticals (搜索), Genentech, Pfizer, and Takeda Pharmaceuticals (搜索), alongside specialized biotechnology firms like Intellia Therapeutics and Precision Biosciences. This diverse mix of large pharmaceutical companies and innovative biotechnology firms reflects the growing recognition of primary hyperoxaluria (搜索) as a therapeutic target with significant unmet medical need.